MRI frequently underestimates tumor size in prostate cancer, finds study
Magnetic Resonance Imaging is frequently used to diagnose and manage prostate cancer. It is also increasingly used as a means to map and guide delivery of new, highly focused therapies that use freezing (cryotherapy), ultrasound (HIFU) and heat (laser ablation) to destroy cancerous tissue in the prostate gland while sparing healthy tissue.
Oncologic efficacy of focal therapies in prostate cancer depends heavily on accurate tumor size estimation. Researchers conducted a study to evaluate the agreement between radiologic tumor size and pathological tumor size, and identify predictors of pathological tumor size.
Multiparametric magnetic resonance imaging frequently underestimates pathological tumor size and the degree of underestimation increases with smaller radiologic tumor size and lower PI-RADSv2 scores. Therefore, a larger ablation margin may be required for smaller tumors and lesions with lower PI-RADSv2 scores. These variables must be considered when estimating treatment margins in focal therapy.